Triple vs double inhaler for uncontrolled asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your doctor has confirmed you have asthma.
- You've been using a medium-strength ICS/LABA inhaler for at least 3 months.
- Your asthma is not well-controlled (symptoms most days and at least one flare-up in the past year).
- You do not have other serious lung conditions or use biologic asthma medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a triple-inhaler called Trimbow for people whose asthma is not well controlled despite using other inhalers. The goal is to see if switching to Trimbow helps reduce asthma attacks and improve day-to-day breathing.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.